Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01704430
Other study ID # MAZ_CVICU_001
Secondary ID
Status Completed
Phase N/A
First received August 22, 2012
Last updated February 6, 2017
Start date September 2012
Est. completion date June 21, 2016

Study information

Verified date February 2017
Source University of Alberta
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patients undergoing heart surgery with a heart-lung machine (termed cardiopulmonary bypass) are at an increased risk of having abnormal "inflammation" in their body after surgery. Such inflammation can contribute to slower recovery from surgery, an increased risk of infection, an increased risk of damage to organs other than the heart, and a more complicated course.

Prior research has suggested that using an oral protein supplement made of glutamine (an essential amino acid normally found in your body) can reduce the risk of inflammation, infection and the length of stay in hospital in patients who have suffered major trauma or a burn injury. The investigators believe reducing such inflammation after heart surgery may help promote recovery and reduce the risk of adverse events and complications.

The purpose of this preliminary study is to see if oral glutamine supplementation after heart surgery is practical, and contributes to a reduction in inflammation. The oral glutamine proposed in this study is based on what has been previously studied and what is considered safe.


Description:

Hypothesis: We believe that early post-operative administration of enteral glutamine following cardiac surgery with cardiopulmonary bypass (CPB) in high risk patients will reduce inflammation and nonscomial infections, reduce length of ventilator support, reduce need for vasoactive support, reduce secondary organ dysfunction, reduce length of hospital stay in the CVICU, and reduce mortality.

Objectives:

- To assess the feasibility of early glutamine supplementation

- To evaluate the safety profile of early glutamine supplementation

- To evaluate efficacy the impact of early glutamine on clinically important post-operative complications and outcomes, including: systemic inflammation, nosocomial infections, mortality, and health resource utilization

Methods: Study Design, Setting, and Patient Population: The proposed study is a Phase II, randomized, blinded, placebo-controlled trial. This trial will be performed in the Cardiovascular Surgical Intensive Care Unit (CVICU) of the Mazankowski Alberta Heart Institute (MAHI), Alberta Health Services. The proposed trial plans to enroll 100 consecutive eligible patients.

Inclusion:

- Consent (obtained pre-operatively)

- Adult - aged 18 years or older;

- Planned cardiac surgery with CPB;

- Elevated risk for post-operative morbidity, defined by a pre-operative European System for Operative Cardiac Risk Evaluation (EuroSCORE) > 6.

- Able to receive enteral nutrition through nasal/oral gastric or post-pyloric feeding tube.

Exclusion:

- Planned heart or lung transplantation

- Planned cardiac surgery without cardiopulmonary bypass;

- Peri-operative support with extracorporeal membrane oxygenation (ECMO) or left ventricular assist device (LVAD).

Study Protocol: Eligible patients will be identified during pre-operative assessment in the pre-operative clinic (PAC). All eligible patients or their surrogate decision-making/legal guardian will then be approached to obtain informed written consent.

Each consenting participant will be randomly allocated (1:1) to receive post-operative enteral glutamine or identical placebo. Investigators, surgeons, intensivists, bedside nurses and participants will remain blinded to study allocation.

Glutamine supplementation will be dosed at 0.5 g/kg satisfactory body weight (SBW)/day divided every 8 hours, starting 6 hours post-operatively and continued for 5 days. The dose of 0.5 g/kg SBW/day was effective in clinical studies using enteral glutamine in critically ill and/or burn injured and major trauma patients. The glutamine supplementation or placebo will be delivered via naso- or oro-gastric feeding tube after confirmation of placement by chest X-ray. For participants who are extubated prior to 5 days, enteral glutamine will be given by mouth for the duration of the 5 day period. Glutamine and placebo will be mixed in orange juice to maintain blinding.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date June 21, 2016
Est. primary completion date June 21, 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Consent (obtained pre-operatively)

- Adult - aged 18 years or older;

- Planned cardiovascular surgery with cardiopulmonary bypass;

- Increased risk for post-operative morbidity, defined by a pre-operative European System for Operative Cardiac Risk Evaluation (EuroSCORE) > 6;

- Able to receive enteral nutrition through nasal/oral gastric or post-pyloric feeding tube.

Exclusion Criteria:

- Planned heart or lung transplantation

- Planned cardiovascular surgery without cardiopulmonary bypass;

- Peri-operative support with extracorporeal membrane oxygenation (ECMO) or left ventricular assist device (LVAD).

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Glutamine
Enteric L-Glutamine
Maltodextrin
Enteric Maltodextrin

Locations

Country Name City State
Canada Mazankowski Alberta Heart Institute, University of Alberta Edmonton Alberta
Canada University of Alberta Edmonton Alberta

Sponsors (1)

Lead Sponsor Collaborator
University of Alberta

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Mortality From the Date of Surgery until Date of Death or 90-days, whichever occurs first
Other Duration of ICU stay Date of surgery until date of hospital discharge, an expected average of 2 weeks
Other Duration of hospital stay Date of surgery until date of hospital discharge, an expected average of 2 weeks
Primary Proportion of Eligible Patients Providing Consent to Participate Assess the FEASIBILITY of the protocol to (i) achieve >75% consent rate in eligible patients Date of surgery until date of hospital discharge, an expected average of 2 weeks
Secondary Acute Kidney Injury Date of surgery until date of hospital discharge, an expected average of 2 weeks
Secondary Duration of mechanical ventilation Date of surgery until date of hospital discharge, an expected average of 2 weeks
Secondary Duration of vasoactive support Date of surgery until date of hospital discharge, an expected average of 2 weeks
Secondary Blood transfusion Date of surgery until date of hospital discharge, an expected average of 2 weeks
Secondary Organ Dysfunction Score Post-operative changes to the Sequential Organ Failure Assessment score Date of surgery until date of hospital discharge, an expected average of 2 weeks
Secondary Adverse events Evaluate the SAFETY and ADVERSE EFFECTS of (i) enteral glutamine; and (ii) COMPLICATIONS from feeding tube placement, including: epistaxis, feeding tube malposition, pneumothorax, esophageal injury, gastric mucosal irritation, gastrointestinal bleeding, unplanned feeding tube removal, and need for feeding tube reinsertion Date of surgery until date of hospital discharge, an expected average of 2 weeks
Secondary Systemic inflammation Systemic Inflammation/immunomodulation: We will evaluate for increases and changes in systemic inflammation stratified by study intervention. This will aid in providing proof-of-concept of the biologic plausibility of the study intervention. The investigators propose to evaluate serial measures of C-reactive protein (CRP), chemiluminescent endotoxin activity assay (EAA), and interleukin-6 (IL-6). Date of surgery until the end of planned study intervention, expected 5-days
Secondary Nosocomial infection Nosocomial infections: The investigators will specifically examine for the following infections during the period of hospitalization after surgery: superficial and deep sternal wound infections; mediastinitis; saphenous vein graft harvest site wound infections; ventilator associated and hospital acquired pneumonia; urinary tract infections; bloodstream infections; catheter-related blood stream infections; and decubitus ulcers. Date of surgery until date of hospital discharge, an expected average of 2 weeks
Secondary Proportion of Randomized Patients Achieving Protocol Adherence Obtain > 90% protocol adherence 5-days (date of surgery until the end of planned study intervention)
See also
  Status Clinical Trial Phase
Completed NCT03365635 - Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C Phase 4
Recruiting NCT05904535 - Novel Diagnostic Methods to Identify External Ventricular Drain Associated Infections
Terminated NCT01225159 - Tight Glycaemic Control During Cardiac Surgery N/A
Recruiting NCT04659356 - NOSOcomial COVID-19 in ICU (NOSOCOVID)
Terminated NCT03423147 - Preoperative Application of Chlorhexidine to Reduce Infection With Cesarean Section After Labor Phase 2
Completed NCT03429283 - Achromobacter Xylosoxidans (ACHX) Infections
Recruiting NCT04252651 - Association of Cytokines With the Development of Complications in Burn and Toxic Epidermal Necrolysis (TENS) Patients
Completed NCT04405934 - COG-UK Project Hospital-Onset COVID-19 Infections Study N/A
Active, not recruiting NCT03865706 - Inulin for Infections in the Intensive Care Unit Phase 2
Recruiting NCT05411562 - COVID-19 Genomic Sequencing for Nosocomial Outbreak Investigations
Completed NCT03250104 - Antibiotic Stewardship and Infection Control in Patients at High Risk of Developing Infection by Clostridium Difficile, Vancomycin-Resistant Enterococci or Multi-Resistant Gram-Negatives
Completed NCT00864929 - An Epidemiological Study on Antimicrobial Treatment of Nosocomial Infections in Clinical Practice N/A
Completed NCT01763008 - A Study of the Safety and Effectiveness of Doripenem in Filipino Patients With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Complicated Urinary Tract Infections Phase 4
Terminated NCT01515020 - Daptomycin Versus Vancomycin in the Treatment of Nosocomial or Healthcare-associated MRSA Bacteremia Phase 3
Active, not recruiting NCT05511129 - Tolerance and Efficacy of Amiklin Administration During Nosocomial Infections Complicating COVID-19 in the ICU
Completed NCT04212130 - Can Environmental Cleanliness be Assessed by BCA (Bicinchoninic Acid) Method N/A
Active, not recruiting NCT05988853 - Biosafety of Musical Instruments in the ICU
Recruiting NCT01943331 - Epidemiological Investigation of CRBSI, VAP, CAUTI in Chinese ICU N/A
Completed NCT00105625 - VA Nutrition Study on Immune Function N/A
Not yet recruiting NCT03857295 - Infections Following NeuroSurgery (INS)